Table 2. Demographic and diseases characteristics of patients in PCSK-9 inhibitor and statins groups before matched.
| Variables | Statins group
(n = 2,610) |
PCSK-9 inhibitor
group (n = 453) |
P-value | Matched
(n = 434) |
Unmatched
(n = 2,176) |
P-value |
| Data are presented as n (%). *Presented as median (interquartile range). PCSK-9: proprotein convertase subtilisin/kexin type 9. | ||||||
| Age, yrs | 59 (52−65)* | 60 (51−68)* | 0.510 | 60 (54−66)* | 59 (51−65)* | 0.002 |
| Male gender | 620 (23.8%) | 311 (68.7%) | < 0.001 | 287 (66.1%) | 332 (15.3%) | < 0.001 |
| Body mass index | 25.71 (23.72−27.78)* | 24.78 (23.29−26.53)* | < 0.001 | 24.58 (23.70−26.34)* | 25.95 (23.95−28.08)* | < 0.001 |
| Hypertension | 1,521 (58.3%) | 302 (66.7%) | 0.001 | 288 (66.4%) | 1,233 (56.7%) | < 0.001 |
| Diabetes mellitus | 730 (28.0%) | 125 (27.6%) | 0.869 | 98 (22.6%) | 632 (29.0%) | < 0.001 |
| Stroke | 172 (6.6%) | 61 (13.5%) | < 0.001 | 60 (13.8%) | 112 (5.1%) | < 0.001 |
| Chronic kidney disease | 19 (0.7%) | 7 (1.5%) | 0.80 | 3 (0.7%) | 16 (0.7%) | 1.000 |
| Smoker | 1,315 (50.4%) | 216 (47.7%) | 0.289 | 106 (24.4%) | 1,209 (55.6%) | < 0.001 |
| Medical history | ||||||
| Myocardial infarction | 225 (8.6%) | 123 (27.2%) | < 0.001 | 24 (5.5%) | 201 (9.2%) | 0.012 |
| Percutaneous coronary intervention | 316 (12.1%) | 90 (19.9%) | < 0.001 | 28 (6.5%) | 288 (13.2%) | < 0.001 |
| Coronary artery bypass graft | 26 (1.0%) | 44 (9.7%) | < 0.001 | 3 (0.7%) | 23 (1.1%) | 0.605 |
| Inpatient diagnose | ||||||
| Stable angina | 231 (8.9%) | 25 (5.5%) | 0.018 | 44 (10.1%) | 187 (8.6%) | 0.301 |
| Unstable angina | 1,589 (60.9%) | 274 (60.5%) | 0.844 | 273 (62.9%) | 1,316 (60.4%) | 0.422 |
| Non-ST-elevation myocardial infarction | 494 (18.9%) | 66 (14.6%) | 0.026 | 73 (16.8%) | 421 (18.9%) | 0.220 |
| ST-elevation myocardial infarction | 292 (11.2%) | 80 (17.7%) | < 0.001 | 44 (10.1%) | 248 (11.4%) | 0.432 |
| Ischemic cardiomyopathy | 4 (0.2%) | 8 (1.8%) | < 0.001 | 0 | 4 (0.2%) | − |
| Laboratory test | ||||||
| Low-density lipoprotein cholesterol, mmol/L | 2.31 (1.78−2.97)* | 3.04 (2.16−4.00)* | < 0.001 | 2.89 (2.19−3.58)* | 2.22 (1.74−2.82)* | < 0.001 |
| High-density lipoprotein cholesterol, mmol/L | 0.97 (0.82−1.14)* | 1.08 (0.92−1.28)* | < 0.001 | 1.08 (0.90−1.24)* | 0.95 (0.81−1.12)* | < 0.001 |
| Total cholesterol, mmol/L | 3.90 (3.30−4.70)* | 4.97 (3.95−6.04)* | < 0.001 | 4.81 (3.98−5.63)* | 3.77 (3.22−4.52)* | < 0.001 |
| Triglycerides, mmol/L | 1.45 (1.04−2.01)* | 1.97 (1.24−3.09)* | < 0.001 | 1.70 (1.15−2.71)* | 1.42 (1.02−1.92)* | < 0.001 |